US FDA Advisory Committee Conduct Could Take Center Stage in Lykos Appeal of MDMA Rejection

 
• By Sarah Karlin-Smith
  
image of large meeting taking place with people around a table and charts of information being displayed.
The advisory committee's focus on information not in the NDA or briefing book will be part of Lykos' CRL appeal. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Complete Response Letters

More from Product Reviews